Hyloris Developmentsen Sa (BR:HYL) — Market Cap & Net Worth
Market Cap & Net Worth: Hyloris Developmentsen Sa (HYL)
Hyloris Developmentsen Sa (BR:HYL) has a market capitalization of $150.58 Million (€128.80 Million) as of June 19, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #17729 globally and #76 in its home market, demonstrating a -6.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hyloris Developmentsen Sa's stock price €4.60 by its total outstanding shares 28000374 (28.00 Million). Review HYL liabilities breakdown to assess the company's total debt and financial obligations.
Hyloris Developmentsen Sa Market Cap History: 2020 to 2026
Hyloris Developmentsen Sa's market capitalization history from 2020 to 2026. Data shows change from $310.99 Million to $150.58 Million (-12.75% CAGR).
Index Memberships
Hyloris Developmentsen Sa is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL All Share
BSPT
|
$854.14 Billion | 0.02% | #80 of 108 |
Weight: Hyloris Developmentsen Sa's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hyloris Developmentsen Sa Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hyloris Developmentsen Sa's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.32x
Hyloris Developmentsen Sa's market cap is 21.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $310.99 Million | $175.00K | -$7.15 Million | 1777.06x | N/A |
| 2021 | $566.32 Million | $3.10 Million | -$11.58 Million | 182.92x | N/A |
| 2022 | $379.73 Million | $2.95 Million | -$11.91 Million | 128.68x | N/A |
| 2023 | $417.38 Million | $2.09 Million | -$15.38 Million | 199.99x | N/A |
| 2024 | $214.09 Million | $10.04 Million | -$6.34 Million | 21.32x | N/A |
Competitor Companies of HYL by Market Capitalization
Companies near Hyloris Developmentsen Sa in the global market cap rankings as of June 19, 2026.
Key companies related to Hyloris Developmentsen Sa by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Hyloris Developmentsen Sa Historical Marketcap From 2020 to 2026
Between 2020 and today, Hyloris Developmentsen Sa's market cap moved from $310.99 Million to $ 150.58 Million, with a yearly change of -12.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €150.58 Million | -32.75% |
| 2025 | €223.91 Million | +4.59% |
| 2024 | €214.09 Million | -48.71% |
| 2023 | €417.38 Million | +9.91% |
| 2022 | €379.73 Million | -32.95% |
| 2021 | €566.32 Million | +82.11% |
| 2020 | €310.99 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Hyloris Developmentsen Sa was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $150.58 Million USD |
| MoneyControl | $150.58 Million USD |
| MarketWatch | $150.58 Million USD |
| marketcap.company | $150.58 Million USD |
| Reuters | $150.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more